These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33339467)

  • 1. Bosutinib - related pleural effusion in patients with chronic myeloid leukemia.
    Yüzbaşıoğlu MB; Eşkazan AE
    Expert Opin Drug Saf; 2021 Apr; 20(4):379-381. PubMed ID: 33339467
    [No Abstract]   [Full Text] [Related]  

  • 2. The safety of Bosutinib for the treatment of chronic myeloid leukemia.
    Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V
    Expert Opin Drug Saf; 2017 Oct; 16(10):1203-1209. PubMed ID: 28774214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
    Caocci G; Mulas O; Abruzzese E; Iurlo A; Annunziata M; Orlandi EM; Galimberti S; Binotto G; Sgherza N; Luciano L; Martino B; Russo Rossi A; Bonifacio M; Fozza C; Trawinska MM; Cattaneo D; Elena C; Baratè C; De Gregorio F; Molica M; La Nasa G; Foà R; Breccia M
    Ann Hematol; 2019 Aug; 98(8):1885-1890. PubMed ID: 31044260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosutinib. Chronic myeloid leukaemia in treatment failure: major toxicity.
    Prescrire Int; 2014 Jul; 23(151):177. PubMed ID: 25162088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.
    Tiribelli M; Abruzzese E; Capodanno I; Sorà F; Trabacchi E; Iurlo A; Luciano L; Binotto G; Bonifacio M; Annunziata M; Crugnola M; Fanin R
    Ann Hematol; 2019 Nov; 98(11):2609-2611. PubMed ID: 31529281
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
    Keller-V Amsberg G; Brümmendorf TH
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1121-7. PubMed ID: 23098112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial).
    Ureshino H; Takahashi N; Ikezoe T; Kameoka Y; Kimura S; Fukushima N; Ichinohe T; Takamori A; Kawaguchi A; Miura M; Kimura S
    Int J Hematol; 2024 Oct; 120(4):492-500. PubMed ID: 39136895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity.
    Riou M; Seferian A; Savale L; Chaumais MC; Guignabert C; Canuet M; Magro P; Rea D; Sitbon O; Jaïs X; Humbert M; Montani D
    Eur Respir J; 2016 Nov; 48(5):1517-1519. PubMed ID: 27799395
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.
    Cortes JE; Gambacorti-Passerini C; Kim DW; Kantarjian HM; Lipton JH; Lahoti A; Talpaz M; Matczak E; Barry E; Leip E; Brümmendorf TH; Khoury HJ
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):684-695.e6. PubMed ID: 28807791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
    García-Gutiérrez V; Milojkovic D; Hernandez-Boluda JC; Claudiani S; Martin Mateos ML; Casado-Montero LF; González G; Jimenez-Velasco A; Boque C; Martinez-Trillos A; Vázquez IM; Payer ÁR; Senín A; Amustio Díez E; García AB; Carrascosa GB; Ortí G; Ruiz BC; Fernández MÁ; Del Carmen García Garay M; Giraldo P; Guinea JM; De Las Heras Rodríguez N; Hernán N; Pérez AI; Piris-Villaespesa M; Lorenzo JLL; Martí-Tutusaus JMM; Vallansot RO; Ortega Rivas F; Puerta JM; Ramirez MJ; Romero E; Romo A; Rosell A; Saavedra SS; Sebrango A; Tallon J; Valencia S; Portero A; Steegmann JL;
    Ann Hematol; 2019 Feb; 98(2):321-330. PubMed ID: 30446802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.
    Cortes JE; Apperley JF; DeAngelo DJ; Deininger MW; Kota VK; Rousselot P; Gambacorti-Passerini C
    J Hematol Oncol; 2018 Dec; 11(1):143. PubMed ID: 30587215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated knuckle hyperpigmentation associated with bosutinib.
    Sharma V; Mahajan S; Bagrodia V
    BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38417948
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
    Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia.
    Khoury HJ; Gambacorti-Passerini C; Brümmendorf TH
    Ann Oncol; 2018 Mar; 29(3):578-587. PubMed ID: 29385394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.
    Caocci G; Mulas O; Annunziata M; Luciano L; Abruzzese E; Bonifacio M; Orlandi EM; Albano F; Galimberti S; Iurlo A; Pregno P; Sgherza N; Martino B; Binotto G; Castagnetti F; Gozzini A; Bocchia M; Fozza C; Stagno F; Simula MP; De Gregorio F; Trawinska MM; Scaffidi L; Elena C; Attolico I; Baratè C; Cattaneo D; Pirillo F; Gugliotta G; Sicuranza A; Molica M; La Nasa G; Foà R; Breccia M
    Int J Cardiol; 2020 Feb; 301():163-166. PubMed ID: 31711851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy.
    Cortes JE; Kantarjian HM; Mauro MJ; An F; Nick S; Leip E; Gambacorti-Passerini C; Brümmendorf TH
    Eur J Haematol; 2021 Jun; 106(6):808-820. PubMed ID: 33638218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.
    Takahashi N; Nakaseko C; Kobayashi Y; Miyamura K; Ono C; Koide Y; Fujii Y; Ohnishi K
    Int J Hematol; 2017 Sep; 106(3):398-410. PubMed ID: 28409328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosutinib for the treatment of chronic myeloid leukemia.
    Doan V; Wang A; Prescott H
    Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic and pharmacodynamic analysis of bosutinib.
    Hsyu PH; Mould DR; Abbas R; Amantea M
    Drug Metab Pharmacokinet; 2014; 29(6):441-8. PubMed ID: 24919837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.